mdco buy littl year away
first inclisiran data market grow
messag debat among investor speak mdco sinc
readout time away mdco requir capit sinc think share
could begin appreci data especi demand appear
grow sequenti y/o/i nrx increas capit need
immin think time next dsmb look expect around
even patient year data could increas comfort inclisiran
long-term safeti believ share could also see upsid potenti market
growth clear safeti look eventu result slightli rais
pt prior reflect result
result vs expect total revenu miss consensu
primari driver non-gaap ep line consensu
mdco end cash equival
guidanc vs consensu per mdco cash suffici data
initi nda file inclisiran compens
inclisiran develop team ytd
spent inclisiran studi ytd
addit spent year outcom studi minim spend
expect trial yet begin expect sg come
mdco restructur headcount less employe
chang estim reflect result modest go forward
safeti still track three dmc look next one like mdco announc
jun data monitor committe dmc conduct yet anoth review
unblind data phase inclisiran studi recommend continu
dmc look efficaci safeti data trial orion program
third clear given sinc start pivot program patient
receiv least two dose inclisiran patient-year safeti data
accumul previous dsmb look safeti data jan patient
post complet enrol patient
patient year safeti data recommend studi continu without chang
modif complet safeti de-risk may assum trial read
least pass clear improv risk-benefit profil
view manag guid nowher near dmc threshold trial
modif view despit small skin reaction seen rate consist
previou studi dsmb also complet discret evalu safeti mdco
previous said review conduct interv complet
trial manag anticip anoth review end
patient would third inject estim
expect data potenti earli certainli
updat could happen earli orion studi month
durat exclud outcom studi includ patient
heterozyg famili hypercholesterolemia hefh patient
atherosclerot cardiovascular diseas ascvd patient
ascvd first readout complet enrol jan
set trial complet end juli data potenti
releas late accord estim follow
complet enrol feb put track complet end
aug data potenti announc earli believ lastli
complet enrol expect complet begin sept
potenti data late estim howev open-label
switch studi repatha could updat earli
page analyst certif import disclosur
inclisiran outcom studi begin need approv believ
natur outcom studi also conduct begin take
year complet view meaning differ inclisiran
antibodi drug competitor durat effect complianc cost even outcom
data potenti way mdco design outcom studi give inclisiran better
likelihood show lower rate death view includ longer durat follow-
stoppag mace alon well endpoint select among other believ
furthermor unlik monoclon antibodi drug includ repatha
regeneron praluent inhibit bind ldl-r inclisiran
inhibit protein synthesi liver cell sinc protein produc ldl-
receptor turnov diminish ldl-c level reduc prolong period
mdco inclisiran also potenti cost advantag mean manufactur
less expens antibodi drug price much competit
prescript trend show market growth acceler pick
follow outcom data yet seen lower price boost demand
combin praluent repatha trx vs
nrx combin praluent repatha
vs growth rate repatha
consist strong follow addit outcom data label
least initi sign posit outcom data lead growth demand
praluent show largest qoq growth sinc vs
follow recent announc lower price valid
hypothesi current could increas volum lower price
posit inclisiran model far lower price either praluent repatha
market continu expand annual run rate vs
expect inclisiran outcom studi design
lead even stronger data
page analyst certif import disclosur
page analyst certif import disclosur
statement mm except per share revenuesnet product sale revenu revenu good gener expens incom income/ incom income/ expens loss incom loss per share per share per share non- per share non- outstand outstand mdco report guggenheim secur llc
page analyst certif import disclosur
pipelineexpect news flowtiminginclisirancompetitor repatha praluent sale post-outcom bempedo acid patient max toler outcom studi updat on-going data homozyg fh develop nda/maa approv outcom studi data denot potenti catalyt eventsourc mdco report guggenheim secur llc estimatespipelinestageindicationangiomaxmarketedpci hit hitt ongoinghypercholesterolemiasourc mdco report
page analyst certif import disclosur
valuat risk
valu mdco per share previous use blend product level dcf price-to-earnings base
valuat includ inclisiran valu per share previous base peak sale world-wide
assum us launch follow launch outsid us assign probabl
success sinc result report trial start read use discount rate
sinc uncertainti busi develop commerci viabil termin
growth rate sinc mdco drug candid small molecul drug potenti driver upsid
model includ increas probabl success clinic regulatori advanc reduc
discount rate base partnership and/or macro event
safeti efficaci issu could emerg inclisiran especi sinc yet test mani
patient dose even longer durat includ outcom studi
drug market could continu lag expect could continu keep inclisiran valu
potenti check
differ make inclisiran stand could diminish time
payer could limit uptak doctors/provid could valu differenti less expect
acquisit partnership inclisiran may forthcom could disappoint investor
page analyst certif import disclosur
